Germline mutations in the RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, MAX, TMEM127, NF1 or VHL genes are identified in about 30% of patients with pheochromocytoma or paraganglioma and somatic mutations in RET, VHL or MAX genes are reported in 17% of sporadic tumors. In the present study, using mutation screening of the NF1 gene, mapping of chromosome aberrations by single nucleotide polymorphism (SNP) array, microarray-based expression profiling and immunohistochemistry (IHC), we addressed the implication of NF1 somatic alterations in pheochromocytomas and paragangliomas. We studied 53 sporadic tumors, selected because of their classification with RET/NF1/TMEM127-related tumors by genome wide expression studies, as well as a second set of 11 independent tumors selected on their low individual levels of NF1 expression evaluated by microarray. Direct sequencing of the NF1 gene in tumor DNA identified the presence of an inactivating NF1 somatic mutation in 41% (25/61) of analyzed sporadic tumors, associated with loss of the wild-type allele in 84% (21/25) of cases. Gene expression signature of NF1-related tumors highlighted the downregulation of NF1 and the major overexpression of SOX9. Among the second set of 11 tumors, two sporadic tumors carried somatic mutations in NF1 as well as in another susceptibility gene. These new findings suggest that NF1 loss of function is a frequent event in the tumorigenesis of sporadic pheochromocytoma and strengthen the new concept of molecular-based targeted therapy for pheochromocytoma or paraganglioma.
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INTRODUCTION
Paragangliomas are neural crest-derived tumors arising from sympathetic and parasympathetic paraganglia. Paragangliomas developed in the adrenal medulla are called pheochromocytomas. About one-third of these tumors occur in a hereditary context and are then linked to a germline mutation in one of the ten susceptibility genes known to date: the RET protooncogene (1) and the SDHA (2), SDHB (3), SDHC (4), SDHD (5), SDHAF2 (6), NF1 (7), VHL (8), TMEM127 (9) and MAX (10) tumor suppressor genes.
Germline mutations in one of these susceptibility genes were described in patients with familial tumor syndromes including multiple endocrine neoplasia type 2 (MEN2), von Hippel Lindau (VHL) disease, neurofibromatosis type 1 (NF1) and familial paraganglioma/pheochromocytoma, but also in 11-19% of patients with a sporadic presentation of pheochromocytoma or paraganglioma (11) (12) (13) (14) (15) (16) .
Until recently, proven somatic mutations (i.e. mutations found in tumor DNA but not in the corresponding germline DNA) in sporadic pheochromocytoma/paraganglioma were identified in VHL, RET, SDHB and SDHD but their frequency was reported to be low (17) (18) (19) (20) . However, we lately reported the occurrence of somatic mutations in VHL and RET genes in 14% of sporadic pheochromocytoma/paraganglioma from the COMETE cohort (21) . Subsequently, we reported one germline and three somatic mutations in the MAX gene within the same cohort (22) .
In the present study, using direct sequencing of the NF1 gene and single nucleotide polymorphism (SNP) array to determine the associated loss of heterozygosity (LOH), we report, for the first time, the high level of NF1 somatic alterations in pheochromocytoma. We demonstrate that 41% (25/61) of the sporadic tumors we analyzed harbor an inactivating somatic mutation in the NF1 gene associated with loss of the wild-type allele in 84% (21/25) of cases.
RESULTS

High frequency of NF1 somatic mutations in pheochromocytoma
To assess the contribution of NF1 somatic mutations in sporadic pheochromocytoma/paraganglioma, NF1 genotyping was performed in a first set of 53 samples. These samples were selected from a large cohort of 202 pheochromocytomas and paragangliomas because, (1) they were classified with RET/ NF1/TMEM127-related tumors (Cluster 2A) in genome wide expression studies (21) ; and (2) they harbored neither germline mutation in the main pheochromocytoma/paraganglioma susceptibility genes nor somatic mutation in RET, TMEM127 and MAX genes (Supplementary Material, Table S1 ). The results are presented in Table 1 .
Twenty-four truncating mutations were identified in the NF1 gene by direct sequencing, including 13 small deletions, one small insertion and one indel, all resulting in a premature stop codon; 4 nonsense mutations; 3 splice mutations leading to exon skipping, confirmed in each case by cDNA analysis; 2 mutations (c.205 -1G.C and c.1885G.A) leading to the creation of a new splice acceptor site and resulting, respectively, in a premature stop codon (p.Arg69Asnfs * 7) and in a partial exon 12b deletion with premature stop codon (p.Gln616Glyfs * 4), described previously (23) . One in-frame deletion of two amino acids (c. 7096_7101del, p.Asn2366_ 2367del) was also found, previously described as likely deleterious (24) .
Finally, we identified one missense variation (c.7532C.T, p.Ala2511Val, rs148154172) with unknown significance, so, it was not considered in further analyses.
In one tumor sample (#167), cDNA analysis revealed two abnormalities in the NF1 gene: the c.5184insA mutation in exon 28 and an exon 19A deletion. The last one was slightly visible on the corresponding electropherograms. The analysis of the corresponding tumor DNA clearly showed the presence of the c.5184insA while the c.3196+2T.G in intron 19A was detected, but at a very low level (Fig. 1A) . In the patient's leucocyte DNA, the c.5184insA was absent but the c.3196+2T.G heterozygous mutation was found (Fig. 1A) . The germline status of the NF1 mutation was also proven in two other patients (#002 and #012) ( Table 1) . In these three patients without previous clinical diagnosis of neurofibromatosis type 1, clinical re-examination revealed very mild features of the disease including clear café-au-lait spots and small perigenito-axillaris lentiginosis. Two of them (#002 and #012) reported a NF1 familial history, which was unknown at the time of pheochromocytoma diagnosis.
Supervised analysis reveals that NF1 and SOX9 are the most under-and over-expressed genes in NF1-mutated tumors, respectively
In light of the samples of our cohort newly associated with NF1 mutations, we re-analyzed the expression data for the 78 tumors classified in Cluster 2A in our previous study (21) . A supervised analysis identified genes significantly deregulated in NF1-mutated tumors. Using a moderate T-test, we found 470 genes significantly upregulated, and 1,021 genes significantly downregulated in NF1-mutated tumors compared with other tumors from Cluster 2A (FDR-adjusted P-value ,0.05, Supplementary Material, Table S2 ). Gene ontology (GO) analysis identified extracellular matrix organization, collagen biosynthetic process, cell adhesion and Wnt receptor signaling pathway as the most significant terms associated with the 470 upregulated genes (P , 0.01). The gene most strongly overexpressed in NF1-mutated tumors was the neural crest transcription factor SOX9 ( Table 2 ). The 1,021 genes significantly underexpressed in NF1-mutated tumors were associated with intracellular protein transport, ncRNA metabolic process, translation and generation of precursor metabolites and energy (P , 0.01). The NF1 gene was the most strongly underexpressed gene in NF1-mutated tumors ( Table 2) .
Analysis of individual microarray values of NF1 expression in Cluster 2A tumors (Fig. 2) revealed that evaluation of NF1 mRNA levels was a powerful criterion to identify NF1-related tumors (harboring germline or somatic mutations). We thus searched for NF1 mutations in 11 additional samples, which harbored a low level of NF1 mRNA expression. They comprised three hereditary tumors with germline mutation (one in SDHB and two in VHL) and eight sporadic tumors
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Human Molecular Genetics, 2012, Vol. 21, No. 26 without germline mutation, including four with a previously identified somatic mutation (one in RET and three in VHL). We identified two NF1 somatic mutations (c.4600delG; p.Ala1534Glufs * 19) and (c.289_888del; p.Gln97_Lys296del) in two out of the four sporadic tumors carrying a previously identified somatic mutation, one in RET and one in VHL gene (Supplementary Material, Table S3 ).
In order to obtain an easy tool, transferable to routine practice, we further evaluated neurofibromin and Sox9 expression at protein level by immunohistochemistry (IHC) on 18 paraffin-embedded tumor samples, which included samples with germline (n ¼ 4) and somatic (n ¼ 7) mutations in the NF1 gene (Supplementary Material, Table S4 ). Tumors were classified according to the level of expression of Table S4 and Fig. S1 ). Almost all non-NF1 mutated samples displayed no or low expression of neurofibromin (6/7) and no or low expression of the Sox9 protein (5/7). We found NF1-mutated tumors with no (n ¼ 2), low (n ¼ 4) or high (n ¼ 5) expression of the neurofibromin. Eight out of the 11 NF1-mutated samples expressed Sox9.
Loss of heterozygosity (LOH) at the NF1 locus is significantly associated with NF1 mutations
The SNP array analysis of the 78 tumors belonging to Cluster 2A revealed LOH at the NF1 locus (17q11.2) in 38 tumors (49%). Twenty-two LOH were large, spanning the whole chromosome 17 or, at least, the entire 17q arm (Supplementary Material, Fig. S2A ), whereas 16 LOH were restricted to the area flanking the NF1 gene locus (focal LOH , 20 Mb, Supplementary Material, Fig. S2B ). Moreover, we detected a homozygous deletion of the NF1 gene in one tumor (#053, Supplementary Material, Fig. S2C and Table 1 ). LOH at the NF1 locus was significantly more frequent in NF1-mutated tumors, whatever the germline or somatic status of the mutation (32/35, 91%), than in other tumors of expression Cluster 2A (6/43, 14%) (P ¼ 2.26 × 10 212 , Fisher's exact test).
Other recurrent chromosome rearrangements in these tumors included 21p, +1q, 23q, 26q, 217p, 221 and 222, and displayed similar frequencies in NF1-, RET-, and tumors without mutation (Supplementary Material, Fig. S3 ).
For sample #167, which carried two different NF1 mutations, the SNP array analysis showed the presence of a large 17q LOH (Fig. 1B) . The comparison of the NF1 sequence electropherograms from the germline and the tumor DNA revealed the loss, by LOH mechanism, of the allele carrying 
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the germline mutation (c.3196+2T.G) in the tumor tissue and the presence of a second mutation (c.5184insA) only in the tumor DNA (Fig. 1A) .
DISCUSSION
In our cohort of sporadic pheochromocytoma/paraganglioma, we previously established the significant contribution of somatic mutations in the VHL (11/119, 9.2%), RET (6/119, 5%) and MAX (3/119, 2.5%) genes (21, 22) . In the present study, we completed the genetic characterization of the cohort and identified a NF1 inactivating somatic mutation in 25/61 of sporadic tumors we analyzed, associated in a majority of cases with LOH at the NF1 locus. The genetic characterization of the COMETE cohort comprising 202 tumors we performed to date is summarized in Figure 3 . Among the NF1-related sporadic tumors, 23 were pheochromocytomas, 1 was an abdominal paraganglioma and 1 was a lymph node metastasis of a pheochromocytoma diagnosed 13 years before. Three out of the 25 tumors were malignant. Altogether, these data clearly show that 36% (43/119) of sporadic pheochromocytoma/paraganglioma harbor, at least, one somatic mutation in pheochromocytoma/paraganglioma susceptibility genes. Fifty-six percent of all somatic mutations identified in our series are carried by the NF1 gene, which should be now considered as the foremost-inactivated gene in sporadic pheochromocytoma.
To our knowledge, the involvement of NF1 somatic alterations was never reported in pheochromocytoma/paraganglioma. However, somatic NF1 mutations were previously identified in 41% (9/22) of sporadic malignant peripheral nerve sheath tumors that are, as pheochromocytomas, neoplasms associated with neurofibromatosis type 1 (24) . Various studies have also identified somatic NF1 alterations in non-neurofibromatosisassociated cancers. Somatic NF1 inactivating mutations or deletions were described in 15 -23% of glioblastoma (25, 26) , 22% of ovarian serous carcinomas (27) , 8% of lung adenocarcinomas (28), 5% of neuroblastoma (29) as well as in acute myeloid leukemia (30) . These data showed that aberration in the NF1 tumor suppressor gene is a key genetic event in tumorigenesis of various cancers, including pheochromocytoma.
Among the NF1 mutations identified in this study, three occurred at a germline level while the clinical diagnosis of neurofibromatosis type 1 had not been previously established for these patients. It is important to note that, in contrast to SDHx, RET, VHL, MAX and TMEM127, the NF1 mutation screening is not performed routinely by molecular genetics laboratories worldwide involved in pheochromocytoma/paraganglioma genetic diagnosis. Indeed, as clinical features of neurofibromatosis type 1 are usually obvious, this diagnosis is currently restricted to the evaluation of clinical criteria (31) . Moreover, the mutation analysis of NF1 by the Sanger method remains a challenge for laboratories, due to the large size of the gene (60 coding exons spanning over 350 kb, 2839 amino acids), the lack of mutation hotspots and the existence of multiple pseudogenes (32) . To our knowledge, only one group reported NF1 mutation screening in patients with apparently sporadic pheochromocytomas (33) . Of the 27 cases, Bausch et al. found one (4%) with a NF1 germline mutation. Clinical re-evaluation of the patient revealed classic, but very mild features of NF1 disease (33) . The description, in the present study, of three similar cases confirms that NF1 germline mutation is not common in apparently sporadic pheochromocytomas and strengthens that a very careful clinical investigation of typical neurofibromatosis type 1 features must be conducted in each patient with pheochromocytoma.
Gene expression and biological pathway analyses performed in NF1-related pheochromocytomas revealed the activation of genes involved in cell differentiation, cell adhesion and motility as well as in cellular and organ developmental processes. This may explain the slight increase in malignant forms of pheochromocytomas observed in NF1-mutated patients, when compared with RET-related ones. Interestingly, SOX9 gene turned out to be the most highly increased in NF1-mutated tumors. Consistently, this gene was also overexpressed in pheochromocytomas developed in Nf1 knockout mice (34) . It was identified as a potential biomarker strongly expressed in neurofibromatosis type 1 relative tumors, and possibly as a therapeutic target in NF1 disease (35) . However, Sox9 immunostaining is not sufficient to identify all NF1-mutated pheochromocytomas. NF1 was the most significantly underexpressed gene in NF1-mutated tumors. Individual values suggested that analysis of its mRNA expression could be a useful tool to suggest the presence of a germline or a somatic NF1 mutation. The identification of two additional NF1 mutations in tumors with low NF1 mRNA expression confirmed this hypothesis. Unfortunately, we were not able to validate this observation at the protein level and neurofibromin IHC was unsuccessful in identifying NF1-mutated samples. To our knowledge, we used the only neurofibromin antibody validated for IHC on paraffin-embedded tissues. Hence, in contrast to SDHB, SDHA and MAX IHC, which can help targeting mutation analysis in SDHx and MAX genes, respectively (22, 36, 37) , neurofibromin IHC is not an efficient tool to select NF1-mutated tumors. However, the sensibility and specificity of neurofibromin and Sox9 IHC should be assessed in larger series of tumors and further investigations should be performed to identify and validate a transferable NF1-mutation prediction tool.
Altogether our data reveal an important contribution of somatic mutations in the genetics of pheochromocytoma and paraganglioma. The combination of all germline and somatic mutation analyses conducted in the COMETE cohort revealed the involvement of one of the ten known susceptibility genes in 60% of cases (121/202), including 78/202 (38.6%) tumors with a germline mutation and 43/202 (21.3%) with a somatic mutation (Fig. 3) . We found germline or somatic NF1 mutations in 37 tumors, making NF1 the second gene involved in the disease, after VHL (40 mutations) and before SDHB (18 mutations) and RET (16 mutations). The other genes (SDHA, SDHC, SDHD, MAX and TMEM127) account for less than five mutations each. Our data also showed the possible association of two somatic mutations in two different pheochromocytoma susceptibility genes (RET and NF1; VHL and NF1) contributing to the tumorigenesis of one sporadic tumor. In the next future, predictive molecular markers should be developed to assess a tailored therapeutic program based on the molecular characterization of the initial tumor that probably should include next generation sequencing methods.
MATERIALS AND METHODS
Ethics statement
Ethical approval for the study was obtained from the institutional review board (CPP Paris-Cochin, January, 2007). All patients provided a written informed consent for the collection of samples and subsequent analyses.
Patients and tumor samples
The tumor and blood samples were prospectively collected by the French "Cortico et Médullosurrénale: les Tumeurs Endocrines" (COMETE) network. The procedures used for pheochromocytoma/paraganglioma diagnosis were in accordance with institutional guidelines and have been described previously (38) . Diagnosis was confirmed by histology in every case. Tumor samples were obtained from patients with pheochromocytomas and/or abdominal or thoracic paragangliomas collected by the Georges Pompidou European Hospital and by the Cochin Hospital, Paris, France. Fresh tumor samples were collected during surgery, immediately frozen and stored in liquid nitrogen until processed. The entire cohort of pheochromocytoma/paraganglioma (referred to as the 'COMETE cohort') includes 202 tumor samples from 190 different and consecutive patients recruited by the COMETE network from 1993 to 2008 as previously described (21) . The present study was first focused on 53 tumor samples selected as follows: (1) lack of germline mutations in RET, VHL, SDHB, SDHC, SDHD, TMEM127 and MAX genes; (2) classification, by unsupervised hierarchical clustering analysis based on the gene expression, with tumors presenting RET, NF1 or TMEM127 germline mutations (i.e. Cluster 2A); and (3) absence of RET, MAX and TMEM127 mutations in tumor DNA.
The second set of tumors we analyzed comprised 11 samples, one with a SDHB germline mutation, two with a VHL germline mutation, three with a VHL somatic mutation, one with a RET somatic mutation and four without identified mutation.
Among the 64 tumor samples, 60 were adrenal pheochromocytomas, 2 were abdominal paragangliomas, 1 was a lymph node metastasis and 1 was a thoracic paraganglioma.
Nucleic acids extraction
Blood DNA, tumor DNA and tumor RNA were extracted as described previously (2) . 
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Gene expression analysis
Microarray analyses were performed with HG-U133 Plus 2.0 Affymetrix GeneChip arrays (Affymetrix) as described previously (21) . A moderate T test, as implemented in the limma Bioconductor package (39) , was used to identify significantly deregulated genes between NF1-mutated and wild-type tumors. We then used DAVID software (40) to detect GO terms significantly enriched in the lists of up-and downregulated genes.
SNP array analysis
Tumor samples were analyzed with Illumina Human610-Quad v1.0 chips, containing 620 901 probes. Hybridization was performed by IntegraGen (Evry, France), according to the instructions provided by the array manufacturer. Raw fluorescent signals were imported into Illumina BeadStudio software and normalized, as previously described (41), to obtain the log R ratio (LRR) and B allele frequency (BAF) for each SNP. The tQN normalization procedure was then applied to correct for the asymmetry in BAF signals due to the bias between the two dyes used in Illumina assays (42) . LOH were determined as previously described (43) . In brief, allelespecific copy numbers were determined using the Genome Alteration Print (GAP) method (44) . We then considered a chromosome region to have undergone LOH when the copy number of the minor copy of the segment was ,0.5. Note that throughout this paper, LOH refers to any chromosome region in which one of the parental copies has been completely lost, whatever the copy number of the retained chromosome. Fisher's exact test was used to compare the frequencies of LOH in diverse tumor subgroups. The SNP data from the 78 tumors analyzed in this study have been deposited in NCBI's gene expression omnibus (GEO) (45) and are accessible through GEO series accession number [GEO: GSE38525].
NF1 genetic analysis
NF1 somatic mutation analysis was performed by sequencing and multiplex ligation-dependent probe amplification (MLPA) as previously described (46) . We performed NF1 mutation screening at both RNA and DNA levels. For each NF1 mutation found in tumor DNA, the corresponding leucocyte DNA was also checked for the presence of the mutation. Mutational screening of NF1 was carried out on RNA through the following procedure. After reverse transcription with Superscript II RNase H-Reverse Transcriptase (Invitrogen), eight overlapping PCR fragments were generated by using FastStart Taq DNA polymerase (Roche). Mutation screening was performed with the ABI BigDye terminator sequencing kit (Applied Biosystems) on an ABI Prism 3130 automatic DNA sequencer (Applied Biosystems). Sequences were aligned with Seqscape w analysis software (Applied Biosystems) and were compared with the corresponding cDNA reference sequence NM_000267. The double strands sequencing of the eight large (from 970 to 1755 bp) overlapped RT-PCR fragments led to characterize almost all the cDNA sequence, except alternative exons 23a, 29 and 30 that were, therefore, sequenced on genomic DNA. Tumor and leucocyte DNA were amplified with specific primers for the 60 coding exons of the NF1 gene and their intervening sequence boundaries, including alternative exon 23a. Owing to the multiple NF1 pseudogenes, the transcript product of the NF1 gene was first sequenced. The double strands sequencing of the RT-PCR products avoids co-amplification of the non-processed pseudogenes. The confirmation of mutations identified at the cDNA level was performed at the DNA level by using specific sense and antisense oligonucleotides of the NF1 active copy. The primer oligonucleotide sequences and PCR conditions are available on request. Sequences were aligned with Seqscape w analysis software (Applied Biosystems) and were compared with the corresponding genomic DNA reference sequences NC_000017.10. In the absence of evidence for pathogenic effect of NF1 variants * Two somatic mutations were identified in two different tumors: one presenting mutations in NF1 and RET and another one harboring mutations in NF1 and VHL genes. (B) A germline mutation in one of the ten pheochromocytoma/paraganglioma susceptibility genes was found in 78 patients, while 43 tumors harbored a somatic mutation. No mutations were identified to date in the remaining set of 81 tumors.
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identified, in silico predictions were performed (ALAMUT w software). NF1 deletion screening was performed by MLPA analysis using the SALSA MLPA kit P081 NF1 mix 1 and SALSA MLPA kit P082 NF1 mix 2, as recommended in the manufacturer's protocol (MRC-Holland, Amsterdam, the Netherlands).
Immunohistochemistry
For IHC study, we used 6 mm sections of paraffin-embedded tissues, mounted on Superfrost plus glass slides.
We used anti-neurofibromin (Santa Cruz Biotechnologies, sc-20982, 1:250) and anti-Sox9 (Millipore, AB5535, 1/500) antibodies and performed heat-mediated antigen retrieval using Tris-EDTA buffer (pH9) for 45 min and citrate buffer (pH6) for 15 min, respectively. As they react with the avidin -biotin-peroxidase complex (Vectastain ABC Elite, Vector Laboratories), we used biotinylated secondary antibody (Vector Laboratories). Peroxidase activity was detected with Histogreen (Abcys). A negative control was performed by omitting the primary antibody. A Leica DM400B microscope was used to perform acquisitions, with 40X objective, thanks to Leica Application Suite software version 2.8.1 and Leica DFC420C camera.
Neurofibromin and Sox9 IHC were performed on 18 paraffin-embedded tumor samples, including 4 samples with NF1 germline mutation, 7 samples with NF1 somatic mutation and 7 non-NF1 mutated samples (2 RET-, 1 VHL-, 1 SDHB-related tumors and 3 tumors without mutation). Slides were coded and classified blindly by two independent observers, according to the level of expression of the protein. Slides presented no expression (score ¼ 0), a low (score ¼ 1) or a high (score ¼ 2) cytoplasmic expression of neurofibromin. For Sox9 expression, slides presented no expression (score ¼ 0), a low (score ¼ 1) or a high (score ¼ 2) nuclear expression of the protein.
